Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CAL -16.2%, OXM -10.4%, AVNW -1.6% (to delay 10-K Filing; sees FY24 revs below consensus)
Other news:
- FULC -69.5% (Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy)
- CURV -15.7% (priced public offering of 8,000,000 shares of the Company's common stock at a price to the public of $4.00/share)
- MRNA -6.9% (provides R&D day highlights progress and strategic priorities; sees FY25 revenue below consensus)
- VNOM -4.2% (prices offering of 10.0 mln shares of common stock at $42.50 per share)
- APLD -2.6% (stock offering)
- CNTA -1.7% ($150 mln stock offering and mixed shelf offering)
- VCTR -1.1% (total AUM for August)
- NSC -0.8% (appoints Mark George as President and CEO; reaffirms FY24 guidance)